Trial Profile
An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Into the Putamen of Subjects With Parkinson's Disease With Fluctuating Responses to Levodopa
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Oct 2021
Price :
$35
*
At a glance
- Drugs Ezaladcigene resoparvovec (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Proof of concept
- Acronyms AADC
- Sponsors Neurocrine Biosciences; Voyager Therapeutics
- 14 Oct 2021 Results reporting final 36-month data from this trial published in the Neurology
- 16 Sep 2020 Preliminary results of three year safety and clinical outcomes presented at the 24th International Congress of Parkinsons Disease and Movement Disorders.
- 11 Sep 2020 According to a Neurocrine Biosciences media release, data from this study were presented today at the MDS Virtual Congress 2020.